Anti-CCR8 Antibody Specificity for Tumor Treg Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CCR8 antibodies in clinical trials are limited to Phase I and lack specificity and efficacy in targeting tumor-infiltrating regulatory T cells without causing systemic autoimmunity.
Innovation Solution
Development of novel anti-CCR8 antibodies and fragments with specific binding to the extracellular domain of CCR8, including human and monkey variants, with enhanced affinity, ADCC activity, and ability to inhibit CCL1-mediated cell migration, while avoiding non-specific binding to CCR4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-CCR8 antibodies are used in clinical trials, then they can target Tregs in the tumor microenvironment, but they lack specificity and efficacy while risking systemic autoimmunity
Solution Approach 1:
The patent applies local quality by engineering the antibody to recognize specific epitopes on CCR8 that are locally present on tumor-infiltrating Tregs but absent or different on thymic Tregs and peripheral blood Tregs. This spatially selective recognition enables the antibody to deplete only the pathogenic Treg population in the tumor microenvironment while preserving systemic Treg homeostasis and avoiding autoimmunity
Solution Approach 2:
The patent employs parameter changes by modifying the antibody's binding affinity and specificity parameters through rational design and optimization. The engineered antibody exhibits enhanced binding affinity for tumor-infiltrating Treg CCR8 while maintaining selective recognition, thereby improving therapeutic efficacy and reducing off-target effects that could cause systemic autoimmunity
2Reliability
If antibodies with high binding affinity to CCR8 are developed, then they can effectively deplete tumor-infiltrating Treg cells, but they may also bind to CCR4 and cause non-specific effects
Solution Approach 1:
The patent applies local quality by designing the antibody to recognize unique structural features or epitopes on CCR8 that distinguish it from CCR4. The antibody's binding interface is engineered to fit specifically with CCR8's extracellular domain configuration, ensuring high affinity for the target receptor while preventing cross-reactivity with the structurally similar CCR4 receptor, thereby eliminating non-specific effects
3Productivity
If novel anti-CCR8 antibodies are designed with enhanced ADCC activity, then they can improve tumor cell killing efficiency, but the complexity of optimizing multiple functions increases
Solution Approach 1:
The patent employs parameter changes by systematically optimizing the antibody's Fc region parameters to enhance ADCC activity. Specific amino acid substitutions in the Fc domain are introduced to increase binding affinity for Fcγ receptors on immune effector cells, thereby amplifying tumor cell killing efficiency. Simultaneously, the variable region parameters are optimized for high CCR8 affinity, achieving multi-functionality through coordinated parameter optimization rather than structural complexity
Solution Approach 2:
The patent applies universality by designing a single antibody molecule that performs multiple functions: high-affinity CCR8 binding for specific Treg recognition, potent ADCC activity for tumor cell killing, and selective depletion of tumor-infiltrating Tregs. This multi-functional antibody simplifies the therapeutic approach compared to combination therapies while achieving comprehensive anti-tumor efficacy through integrated molecular design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies demonstrate strong binding to primate CCR8, high ADCC and ADCP activities, and effective inhibition of CCL1-mediated cell migration, offering potential therapeutic benefits for cancer treatment by depleting tumor-infiltrating Treg cells.
Implementation Method 1
The antibody specifically binds to one or more amino acids in the extracellular domain of CCR8
Implementation Method 2
high ADCC and ADCP activities
Data Source
AI summary
An antibody specifically binding to CCR8, an antibody fragment, an antigen-binding part thereof, and the related use. The anti-CCR8 antibody has a differentiation advantage of targeting CCR8, thereby providing a medication choice and therapeutic regimen for tumor patients.